A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoMix 30 FlexPen as Monotherapy, or in Combination With OHA, in Treatment of Type 2 Diabetic Patients in Routine Clinical Practice: A Post-Marketing Surveillance Study.
Phase of Trial: Phase IV
Latest Information Update: 15 Dec 2016
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms CEEP
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 23 May 2012 Official title amended as reported by ClinicalTrials.gov.
- 09 Oct 2009 Actual patient number changed from 1296 to 1584 as reported by ClinicalTrials.gov.